Stocks · News reference
Wolfe Research Downgrades Corcept Therapeutics to Underperform, Announces $50 Price Target
Wolfe Research analyst Kalpit Patel downgrades Corcept Therapeutics (NASDAQ:CORT) from Peer Perform to Underperform and announces $50 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 27, 2026, 11:59 AM
- Checked
- Jul 27, 2026, 11:59 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Stock Market Today: Microsoft Ignites Chip Rebound as SanDisk Jumps 24%
Microsoft's 43% cloud growth revived the AI trade and lifted chipmakers, but Meta's guidance miss and a 19-year high in 30-year yields capped the rebound.
Read original at benzingaCanaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $161
Read original at benzingaLam Research, Xerox, FormFactor, Microsoft And Other Big Stocks Moving Higher On Thursday
Dow Jones index gained 300 points, Lam Research Corp rose 20.1% after reporting strong financial results. Xerox, Columbus McKinnon, and other stocks recorded gains.
Read original at benzinga